Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2026 | The growing prognostic and clinical value of ctDNA in solid tumors

Scott Kopetz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the growing prognostic and clinical value of circulating tumor DNA (ctDNA) in solid tumors. He highlights the role of ctDNA in assessing treatment response, identifying minimal residual disease (MRD), and guiding personalized treatment strategies. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.a